secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277555
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio to merge with Lenz Therapeutics; Lenz holders to own 65%
---------------------------------------------------------------------

- Graphite valued at $126.5M, LENZ at $231.6M; $60M cash dividend to pre-merger Graphite stockholders.
- LENZ stockholders will own ~65% of combined company, Graphite ~35% on fully-diluted basis.
- Concurrent PIPE investment of $53.5M (minimum $50M, up to $125M) to close alongside merger.
- Post-merger board: 7 members (5 from LENZ, 2 from Graphite); company renamed LENZ Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000119312523277555/0001193125-23-277555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000119312523277555/d896516d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer